An Increase in Imported Plasmodium vivax Malaria in New York City: Clinical and Demographic Trends Following Recent Migration
Clicks: 1
ID: 313397
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #125 of 208 articles by views in Open forum infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 208 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Plasmodium vivax causes over 9 million malaria cases globally. While rare in the U.S., New York City (NYC) reports the highest number of travel-associated cases. In 2023, cases peaked alongside the arrival of > 265,000 migrants from malaria-endemic regions. Methods We retrospectively reviewed P. vivax cases reported to the NYC Department of Health (2018–2024), and analyzed clinical data from patients admitted to NYC Health + Hospitals (H+H) over the same period. Cases were confirmed via blood smear, rapid diagnostic test (RDT), or polymerase chain reaction (PCR). Data on travel history, presentation, diagnostics, treatment, and outcomes were analyzed. Results In NYC, the number of P. vivax cases rose from 6 of 206 malaria cases (2.9%) in 2018 to a record 63 of 346 (18.2%) in 2023, with 43 of 250 (17.2%) in 2024. Of 41 H+H admissions, 40 (97.6%) were recent migrants, mainly from South America and Asia. Severe malaria occurred in 10 patients (24.4%), with 5 (12.2%) requiring intensive care. RDTs were used in 38 cases (93%); PCR had a median 8-day turnaround. Primaquine was prescribed to 32 (78%) after G6PD testing. Relapses occurred in 7 patients (17%), mostly among those not receiving liver-stage therapy. Conclusions The rise in P. vivax malaria in NYC parallels migration trends from endemic areas. Timely diagnosis and liver-stage therapy are critical to reducing morbidity and relapses. While nearly all cases were imported, delayed species confirmation or incomplete treatment risks potential local transmission, requiring heightened clinician awareness and public health vigilance.
| Reference Key |
openalex_W7161410325
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Cesar G. Berto, Maria Alyssa Policarpio, Coral Vargas-Pena, Mike Antwi, Sally Slavinski, Asha Abdool, Renee King, Tsoline Kojaoghlanian, Johanna P. Daily, Nishant Prasad, Maria Rosa Velasquez, Alison Ridpath, Christina Coyle |
| Journal | Open forum infectious diseases |
| Year | 2026 |
| DOI |
10.1093/ofid/ofag293
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.